The Mulhouse medical biotechnology start-up CellProthera, pioneer of cell regeneration, just raised 4,4 million euros. A fundraising event following a year 2022 rich in medical advances, scientific and regulatory. The year 2023 looks promising parliament.
L’ company develops a unique therapy in the world regenerating heart tissue damaged by a heart attack thanks to the implantation of stem cells. The most : the latter are collected by a simple blood test, then multiplied in a specific automaton. They are then injected into the area to be repaired.
Result : no rejection possible since the patient becomes his own medicine. In certain cases, this therapy represents an effective alternative to heart transplantation.. The start-up has carried out promising preclinical trials on the use of its solution in the treatment of stroke in collaboration with South Florida University, In France, in the United Kingdom and Singapore on patients who have already suffered a severe myocardial infarction. Forte the’ these first proud results, she is planning a first clinical study in humans. For this purpose, the start-up carried out a fundraising campaign in March which allowed it to collect 4,4 million euros. “Thanks to this fundraising, we can accelerate our development, explains Matthieu de Kalbermatten, president of CellProthera. By the end of the year, we should finalize the recruitment of patients for our study “Excellent” ».
Launch of a clinical study in humans
For a year, CellProthera is experiencing an unprecedented pace of patient recruitment : five times more patients than before were recruited, and this rhythm is confirmed at the start of 2023 in all partner centers in France and the United Kingdom. Two new centers have joined clinical trials : The Scottish hospital in Dundee and the Mulhouse hospital center. In total, there are less than 10 patients left to recruit to launch the clinical study. In parallel, the Mulhouse company continues its efforts to optimize the manufacturing process, so that it meets the requirements of regulatory authorities and is ready for the next phases of clinical development and commercialization. Finally, CellProthera obtained IS0 13485 certification:2016, certifying the compliance of the bioproduction equipment developed with medical device regulations, as well as the certificate of conformity to good manufacturing practices (GMP) and which confirms the pharmaceutical establishment status of CellProthera.
